Abstract: In one aspect, the invention provides a process for the production of 5-(4-Fluoro-phenyl)-2-isopropyl-4-phenyl-1-(3,5,7-trihydroxy-heptyl)-1H-pyrrole-3-carboxylic acid phenylamide hemicalcium salt, stereoisomers thereof or polymorphs thereof from a (6-{2-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2]dioxaborinan-4-yl)-acetic acid tert-butyl ester.

Abstract: The present invention relates to a novel crystalline form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing the same.

Abstract: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin rosuvastatin, pitavastatin, and fluvastatin.

Abstract: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin.

Abstract: In one aspect, the invention provides a process for the preparation of compounds of Formula I wherein R1 is —CN, —OP, alkyl, aryl or heteroaryl; wherein P represents any suitable protecting group; and R2 is alkyl or aryl; by reacting a compound of Formula II wherein R1 is —CN, —OP, alkyl, aryl or heteroaryl; wherein P represents any suitable protecting group; and R2 is alkyl or aryl; with a reducing agent (e.g. sodium borohydride) in the presence of a metal halid (e.g. CeCl3) or a metal alkoxid (e.g. Ti(OiPr)4).

Abstract: In one aspect, the invention provides a process for the preparation of an amorphous HMG-CoA reductase inhibitor and hydrates thereof of desired particle size, which comprises: dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent, and removing the solvent by freeze-drying.

Abstract: In one aspect, the present invention provides an improved method for the manufacture of Pravastatin sodium salt by fermentation under optimal fermentation parameters using a new strain of Streptomyces flavidovirens.

Abstract: In one aspect, the invention provides a process for the preparation of a compound of Formula I wherein G is alkyl or aryl, by employing a novel halo-substituted active methylene compound of Formula III wherein X is halogen, and process of preparation thereof.

Abstract: In one aspect, the invention provides a process for the production of 5-(4-Fluoro-phenyl)-2-isopropyl-4-phenyl-1-(3,5,7-trihydroxy-heptyl)-1H-pyrrole-3-carboxylic acid phenylamide hemicalcium salt, stereoisomers thereof or polymorphs thereof from a (6-{2-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2]dioxaborinan-4-yl)-acetic acid tert-butyl ester.

Abstract: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin.

Abstract: The present invention relates to a novel crystalline form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing the same.

Abstract: The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin rosuvastatin, pitavastatin, and fluvastatin.

Abstract: A novel process for the preparation of compounds of formula I by employing novel halo-substituted active methylene compounds of formula III and process of preparation thereof.

Abstract: The present invention discusses a novel process for the synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium, atorvastatin. The compound so prepared is useful as inhibitor of the HMG-CoA reductase and may thus be used as hypolipidemic and hypocholesterolemic agent.

Abstract: In one aspect, the invention provides a process for the preparation of compounds of Formula I 1

Abstract: In one aspect, the invention provides a solid catalyst comprising an active alumina catalyst impregnated with a metal hydroxide. In another aspect, the invention provides a process for preparing the inventive alumina catalyst. In certain embodiments, the catalyst may be used for the protection of amines, alcohols and thiols with a wide variety of protecting agents. This procedure is widely applicable for N-protection of amino acids which finds wide industrial applications. The catalyst is also useful for carrying out nucleophilic substitutions of aromatic halides containing an electron-withdrawing group. A wide variety of nucleophiles chosen from amines, primary and secondary, aromatic and aliphatic, as well as alcohols and thiols have been successfully employed. The methodology involves simple techniques and easy work up procedures and is thus useful for large-scale industrial preparations. Additionally, the reactions avoid the use of harmful solvents and thus satisfy the need for green chemistry.

Abstract: In one aspect, the present invention provides an improved method for the manufacture of Pravastatin sodium salt by fermentation under optimal fermentation parameters using a new strain of Streptomyces flavidovirens.

Abstract: A process for the preparation of amorphous HMG-CoA reductase inhibitor and its hydrates thereof of desired particle size, which comprises: (a) dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent; (b) removing the solvent by freeze-drying.

Abstract: The present invention discusses a novel process for the synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-B,D-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium, atorvastatin. The compound so prepared is useful as inhibitor of the enzyme HMG-CoA reductase and may thus be used as hypolipidemic and hypocholesterolemic agent.

Abstract: Methods for the manufacture of Mycophenolate are disclosed. Mycophenblate mofetil is biochemically synthesized using Mycophenolic Acid and 2-morpholino ethanol with the help of an enzyme. Mycophenolate mofetil is also chemically synthesized non-catalytically by refluxing mycophenolic acid with 2-morpholino ethanol in the absence of a third solvent or a catalyst.